NCT02206607 - Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

PF-04937319 IR MST

Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch

DRUG

PF-04937319 MR 1

Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

DRUG

PF-04937319 MR 2

Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

DRUG

PF-04937319 MR 3

Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST

Trial Locations (2)

High Point Clinical Trials Center, High Point

Clinical Trials of Texas, Inc., San Antonio